COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

bioRxiv posts many COVID19-related papers. A reminder: they have not been formally peer-reviewed and should not guide health-related behavior or be reported in the press as conclusive.

29,034 Articles (21,527 medRxiv, 7,507 bioRxiv)

Most recent first Previous |  Page 12: Articles 111-120  | Next

Broadly neutralizing antibodies against emerging delta-coronaviruses
Rexhepaj, M., Park, Y.-J., Perruzza, L., Asarnow, D., McCallum, M., Culap, K., Saliba, C., Leoni, G., Balmeli, A., Yoshiyama, C., Dickinson, M. S., Quispe, J., Brown, J. T., Tortorici, M. A., Sprouse, K. R., Taylor, A. L., Starr, T. N., Corti, D., Begnini, F., Veesler, D.
10.1101/2024.03.27.586411 — Posted: 2024-04-01
Healthcare workers compliance with COVID-19 preventive and control measures at De Martino Hospital, Mogadishu, Somalia
Janay, A. I., Kilic, B., Unal, B.
10.1101/2024.03.29.24305060 — Posted: 2024-03-30
Patients with COVID-19 Infection and Stroke have Higher than Expected Mortality, Regardless of the Primary Presentation
Liu, J., Fu, E., Gillette, R., Wohlauer, M.
10.1101/2024.03.29.24305101 — Posted: 2024-03-30
Effectiveness of Autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study.
Kirsebom, F., Stowe, J., Lopez Bernal, J., Allen, A., Andrews, N.
10.1101/2024.03.28.24305030 — Posted: 2024-03-29
Abolished frameshifting for predicted structure-stabilizing SARS-CoV-2 mutants: Implications to alternative conformations and their statistical structural analyses
Dey, A., Laederach, A., Yan, S., Schlick, T.
10.1101/2024.03.28.586935 — Posted: 2024-03-29
Three Modes of Viral Adaption by the Heart
Griffiths, C. D., Shah, M., Shao, W., Borgman, C. A., Janes, K. A.
10.1101/2024.03.28.587274 — Posted: 2024-03-29
Broad-Spectrum Coronavirus Inhibitors Discovered by Modeling Viral Fusion Dynamics
Reilly, C. B., Moore, J., Lightbown, S., Paul, A. J., Bernier, S. G., Carlson, K. E., Ingber, D. D.
10.1101/2024.03.28.587229 — Posted: 2024-03-29
Enhanced mucosal B- and T-cell responses against SARS-CoV-2 after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant.
Laghlali, G., Wiest, M. J., Karada, D., Warang, P., O'Konek, J. J., Chang, L. A., Park, S., Farazuddin, M., Landers, J. J., Janczak, K. W., Garcia-Sastre, A., Baker, J. R., Wong, P. T., Schotsaert, M.
10.1101/2024.03.28.587260 — Posted: 2024-03-29
Does behavior mediate the effect of weather on SARS-CoV-2 transmission? Evidence from cell-phone data
Grover, E. N., Buchwald, A. G., Ghosh, D., Carlton, E. J.
10.1101/2024.03.26.24304854 — Posted: 2024-03-28
The 10-year health impact, economic impact, and return on investment of the South African molecular diagnostics programme for HIV, Tuberculosis and SARS-CoV-2
Nichols, B. E., de Nooy, A., Cassim, N., Hans, L., da Silva, M. P., Chetty, K., Grantz, K. H., Han, A. X., Phillips, A. N., Jamieson, L., Scott, L. E., Stevens, W. S.
10.1101/2024.03.27.24304888 — Posted: 2024-03-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).